MEREO BIOPHARMA GROUP PLC
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $92.2M | — |
| FY2022 | — | $51.4M | $68.2M |
| FY2023 | — | $50.5M | $57.4M |
| FY2024 | — | $61.0M | $69.8M |
| FY2025 | — | $40.9M | $41.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $92.2M | — |
| FY2022 | — | $51.4M | $68.2M |
| FY2023 | — | $50.5M | $57.4M |
| FY2024 | — | $61.0M | $69.8M |
| FY2025 | — | $40.9M | $41.0M |